The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis

Background:In the era of antiretroviral therapy, non-AIDS complications such as kidney disease are important contributors to morbidity and mortality. Objective:To estimate the impact of hepatitis C coinfection on the risk of kidney disease in HIV patients. Design and methods:Two investigators identified English-language citations in MEDLINE and Web of Science from 1989 through 1 July 2007. References of selected articles were reviewed. Observational studies and clinical trials of HIV-related kidney disease and antiretroviral nephrotoxicity were eligible if they included at least 50 subjects and reported hepatitis C status. Data on study characteristics, population, and kidney disease outcomes were abstracted by two independent reviewers. Results:After screening 2516 articles, 27 studies were eligible and 24 authors confirmed or provided data. Separate meta-analyses were performed for chronic kidney disease outcomes (n = 10), proteinuria (n = 4), acute renal failure (n = 2), and indinavir toxicity (n = 5). The pooled incidence of chronic kidney disease was higher in patients with hepatitis C coinfection [6.2 versus 4.0%; relative risk 1.49, 95% confidence interval (CI) 1.08–2.06]. In meta-regression, prevalence of black race and the proportion of patients with documented hepatitis C status were independently associated with the risk of chronic kidney disease. The relative risk associated with hepatitis C coinfection was significantly increased for proteinuria (1.15; 95% CI 1.02–1.30) and acute renal failure (1.64; 95% CI 1.21–2.23), with no significant statistical heterogeneity. The relative risk of indinavir toxicity was 1.59 (95% CI 0.99–2.54) with hepatitis C coinfection. Conclusion:Hepatitis C coinfection is associated with a significant increase in the risk of HIV-related kidney disease.

[1]  Richard D Moore,et al.  End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004 , 2007, AIDS.

[2]  P. Volberding,et al.  Racial differences in end-stage renal disease rates in HIV infection versus diabetes. , 2007, Journal of the American Society of Nephrology : JASN.

[3]  I. Barash,et al.  Chronic kidney disease in HIV infection: an urban epidemic , 2007, AIDS.

[4]  E. Vittinghoff,et al.  Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. , 2007, Archives of internal medicine.

[5]  P. Klotman,et al.  Efavirenz: innocent bystander or direct nephrotoxin? , 2007, AIDS.

[6]  A. Mocroft,et al.  Chronic renal failure among HIV-1-infected patients , 2007, AIDS.

[7]  S. Sidney,et al.  Microalbuminuria in HIV infection , 2007, AIDS.

[8]  K. Delaney,et al.  Recurrence rates in patients with first episodes of acute pancreatitis , 2007, Critical Care.

[9]  F. Antunes,et al.  Acute renal failure in critically ill HIV-infected patients , 2007, Critical care.

[10]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[11]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[12]  L. Szczech,et al.  Immunosuppression, Hepatitis C Infection, and Acute Renal Failure in HIV-Infected Patients , 2006, Journal of acquired immune deficiency syndromes.

[13]  S. Tezenas du Montcel,et al.  Changing Electrolyte and Acido-Basic Profile in HIV-Infected Patients in the HAART Era , 2006, Nephron Physiology.

[14]  E. Vittinghoff,et al.  Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  Jill Hayden,et al.  Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.

[16]  A. Winston,et al.  Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy , 2006, HIV medicine.

[17]  P. Klotman,et al.  Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality , 2006, AIDS.

[18]  M. Alter,et al.  Epidemiology of viral hepatitis and HIV co-infection. , 2006, Journal of hepatology.

[19]  L. Szczech,et al.  Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. , 2005, Journal of the American Society of Nephrology : JASN.

[20]  F. Gutiérrez,et al.  Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. , 2005, AIDS patient care and STDs.

[21]  K. Tashima,et al.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Stephen R Cole,et al.  Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. , 2005, Archives of internal medicine.

[23]  Richard D Moore,et al.  Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  L. Szczech,et al.  Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. , 2005, Kidney international.

[25]  G. Mcgwin,et al.  Factors associated with chronic renal failure in HIV-infected ambulatory patients , 2004, AIDS.

[26]  J. Feinberg,et al.  HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  L. Svetkey,et al.  The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. , 2004, Kidney international.

[28]  S. Staszewski,et al.  Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  R. Salamon,et al.  Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  K. Koike,et al.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.

[31]  Richard D Moore,et al.  Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study , 2004, AIDS.

[32]  B. Mamlin,et al.  Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. , 2004, Clinical nephrology.

[33]  J. Neaton,et al.  Grade 4 Events Are as Important as AIDS Events in the Era of HAART , 2003, Journal of acquired immune deficiency syndromes.

[34]  K. Tashima,et al.  Rates and Risk Factors for Condition‐Specific Hospitalizations in HIV‐Infected and Uninfected Women , 2003, Journal of acquired immune deficiency syndromes.

[35]  B. Evatt,et al.  Renal disease among males with haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[36]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[37]  L. Szczech,et al.  Development of Proteinuria or Elevated Serum Creatinine and Mortality in HIV-Infected Women , 2003, Journal of acquired immune deficiency syndromes.

[38]  A. Moorman,et al.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  B. G. Blijenberg,et al.  Persistent Leukocyturia and Loss of Renal Function in a Prospectively Monitored Cohort of HIV-Infected Patients Treated with Indinavir , 2003, Journal of acquired immune deficiency syndromes.

[40]  M. Perazella,et al.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. , 2002, The American journal of the medical sciences.

[41]  F. del Sorbo,et al.  Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. , 2002, AIDS.

[42]  R. Willson.  Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. , 2002, Journal of clinical gastroenterology.

[43]  R. Byers,et al.  Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987‐1999 , 2002, Journal of acquired immune deficiency syndromes.

[44]  Mardge H. Cohen,et al.  Predictors of proteinuria and renal failure among women with HIV infection. , 2002, Kidney international.

[45]  L. Agodoa,et al.  Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. , 2001, Journal of nephrology.

[46]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.

[48]  M. Szklo,et al.  Prevalence of Type 2 Diabetes Mellitus among Persons with Hepatitis C Virus Infection in the United States , 2000, Annals of Internal Medicine.

[49]  V. Shahinian,et al.  Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[51]  J. Izopet,et al.  Increased Incidence of Indinavir Nephrolithiasis in Patients with Hepatitis B or C Virus Infection , 2000, Antiviral therapy.

[52]  V. Shahinian,et al.  Is the Prevalence of HIV-Associated Nephropathy Decreasing? , 1999, American Journal of Nephrology.

[53]  P. Sax,et al.  Variation in incidence of indinavir‐associated nephrolithiasis among HIV‐positive patients , 1998, AIDS.

[54]  P. Simmonds,et al.  Extrahepatic Immunologic Manifestations in Chronic Hepatitis C and Hepatitis C Virus Serotypes , 1995, Annals of Internal Medicine.

[55]  R. Rodby,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. , 1993, Journal of the American Society of Nephrology : JASN.

[56]  H J Alter,et al.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. , 1990, Science.

[57]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.